Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic-tandem mass spectrometric method

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 523-528

  Srivastava, Abhishek ^a   Waterhouse, David ^a   Ardrey, Alison ^a   Ward, Stephen A ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cerebrospinal fluid; Human plasma; LC MS MS; Quantitative assay; Rifampicin; Validation

Indexed keywords

ORGANIC SOLVENT; RIFAMPICIN; RIFAPENTINE;

ACCURACY; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CENTRIFUGATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG HALF LIFE; DRUG ISOLATION; DRUG STABILITY; ELECTROPHORESIS; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE REACTION MONITORING; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CALIBRATION; CENTRIFUGATION; CHEMICAL PRECIPITATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; HUMANS; LIMIT OF DETECTION; LINEAR MODELS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SOLVENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84866242540     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.05.028     Document Type: Article

References (26)

1. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., Dye C. Tuberculosis. Lancet 2003, 362:887-899.
2. Kaufmann S.H.E. Is the development of a new tuberculosis vaccine possible?. Nat. Med. 2000, 6:955-960.
3. Blumberg H.M., Burman W.J., Chaisson R.E., Daley C.L., Etkind S.C., Friedman L.N., Fujiwara P., Grzemska M., Hopewell P.C., Iseman M.D., Jasmer R.M., Koppaka V., Menzies R.I., O'Brien R.J., Reves R.R., Reichman L.B., Simone P.M., Starke J.R., Vernon A.A. American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 2003, 167:603-662.
4. Rees R.J.W., Pearson J.M.H., Waters M.F.R. Experimental and clinical studies on rifampicin in treatment of leprosy. Br. Med. J. 1970, 1:89-92.
5. Bakker M.I., Hatta M., Kwenang A., Van Benthem B.H., Van Beers S.M., Klatser P.R., Oskam L. Prevention of leprosy using rifampicin as chemoprophylaxis. Am. J. Trop. Med. Hyg. 2005, 72:443-448.
6. Perlroth J., Kuo M., Tan J., Bayer A.S., Miller L.G. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch. Intern. Med. 2008, 168:805-819.
7. Udupa N., Goyal P., Agarwal S., Venkatesh S., Pandey S. Simultaneous HPTLC determination of rifampicin and isoniazid in rat plasma. Indian J. Pharm. Sci. 2003, 65:414-416.
8. Calleja I., Blanco-Príeto M.J., Ruz N., Renedo M.J., Dios-Viéitez M.C. High-performance liquid-chromatographic determination of rifampicin in plasma and tissues. J. Chromatogr. A 2004, 1031:289-294.
9. Khuhawar M.Y., Rind F.M.A. Liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin from pharmaceutical preparations and blood. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 766:357-363.
10. Calleri E., De Lorenzi E., Furlanetto S., Massolini G., Caccialanza G. Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation. J. Pharm. Biomed. Anal. 2002, 29:1089-1096.
11. Mohan B., Sharda N., Singh S. Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin. J. Pharm. Biomed. Anal. 2003, 31:607-612.
12. Walubo A., Smith P., Folb P.I. Comprehensive assay for pyrazinamide, rifampicin and isoniazid with its hydrazine metabolites in human plasma by column liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1994, 658:391-396.
13. Woo J., Wong C.L., Teoh R., Chan K. Liquid chromatographic assay for the simultaneous determination of pyrazinamide and rifampicin in serum samples from patients with tuberculosis meningitis. J. Chromatogr. B: Biomed. Sci. Appl. 1987, 420:73-80.
14. Ishii M., Ogata H. Determination of rifampicin and its main metabolites in human plasma by high-performance liquid chromatography. J. Chromatogr. B: Biomed. Sci. Appl. 1988, 426:412-416.
15. Seifart H.I., Kruger P.B., Parkin D.P., van Jaarsveld P.P., Donald P.R. Therapeutic monitoring of antituberculosis drugs by direct in-line extraction on a high-performance liquid chromatography system. J. Chromatogr. Biomed. Appl. 1993, 619:285-290.
16. Ratti B., Parenti R.R., Toselli A., Zerilli L.F. Quantitative assay of rifampicin and its main metabolite 25-desacetylrifampicin in human plasma by reversed-phase high-performance liquid chromatography. J. Chromatogr. B: Biomed. Sci. Appl. 1981, 225:526-531.
17. Smith P.J., Dyk J.v., Fredericks A. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. Int. J. Tuberc. Lung Dis. 1999, 3:S325-S328.
18. Balbão M.S., Bertucci C., Bergamaschi M.M., Queiroz R.H.C., Malfará W.R., Dreossi S.A.C., de Paula Mello L., Queiroz M.E.C. Rifampicin determination in plasma by stir bar-sorptive extraction and liquid chromatography. J. Pharm. Biomed. Anal. 2010, 51:1078-1083.
19. Gikas E., Bazoti F.N., Fanourgiakis P., Perivolioti E., Roussidis A., Skoutelis A., Tsarbopoulos A. Simultaneous quantification of daptomycin and rifampicin in plasma by ultra performance liquid chromatography: application to a pharmacokinetic study. J. Pharm. Biomed. Anal. 2010, 51:901-906.
20. Hartkoorn R.C., Khoo S., Back D.J., Tjia J.F., Waitt C.J., Chaponda M., Davies G., Ardrey A., Ashleigh S., Ward S.A. A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 857:76-82.
21. Korfmacher W.A., Bloom J., Churchwell M.I., Getek T.A., Hansen E.B., Holder C.L., McManus K.T. Characterization of three rifamycins via electrospray mass spectrometry and HPLC-thermospray mass spectrometry. J. Chromatogr. Sci. 1993, 31:498-501.
22. Baietto L., D'Avolio A., De Rosa F.G., Garazzino S., Michelazzo M., Ventimiglia G., Siccardi M., Simiele M., Sciandra M., Di Perri G. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Anal. Bioanal. Chem. 2010, 396:791-798.
23. de Velde F., Alffenaar J.W.C., Wessels A.M.A., Greijdanus B., Uges D.R.A. Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:1771-1777.
24. Notari S., Mancone C., Sergi M., Gullotta F., Bevilacqua N., Tempestilli M., Urso R., Lauria F.N., Pucillo L.P., Tripodi M., Ascenzi P. Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF. IUBMB Life 2010, 62:387-393.
25. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research, 2001.
26. Hanpithakpong W., Kamanikom B., Dondorp A.M., Singhasivanon P., White N.J., Day N.P.J., Lindegardh N. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 876:61-68.